Joseph de Wet

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 91 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Chloe Orkin, Edwin DeJesus, Moti Ramgopal et al. · The Lancet HIV · 2017 · 76 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

Grace A. McComsey, Sergio Lupo, David Parks et al. · AIDS · 2017 · 57 citations · Full text

Pharmacy, Pharmacotherapy, Bone Metabolism +16

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Edwin DeJesus, Moti Ramgopal, Gordon Crofoot et al. · The Lancet HIV · 2017 · 48 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of gender and race on the week 48 findings in treatment‐naïve, <scp>HIV</scp>‐1‐infected patients enrolled in the randomized, phase <scp>III</scp> trials <scp>ECHO</scp> and <scp>THRIVE</scp>

Sally Hodder, Keikawus Arastéh, Joseph de Wet et al. · HIV Medicine · 2012 · 44 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17